Inogen reports prelim Q4 rev $79M-$80M (+4-5%); FY24 rev $334.5M-$335.5M (+6%), beats guidance

Inogen Inc

2024-FY EPS reported -$1.52 revenue$335,705,000

Q4 2024 preliminary revenue of $79M-$80M, up 4-5% YoY.
Full-year 2024 preliminary revenue of $334.5M-$335.5M, up 6% YoY, exceeding prior guidance of $329M-$331M.
Driven by strong double-digit B2B revenue growth; DTC revenue stabilization ongoing.
Launched Rove 4 and received FDA clearance for SIMEOX 200 during Q4.
Official Q4/FY results and conference call scheduled for Feb 25, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.